NYSE American · Biotechnology

MAIA Biotechnology, Inc. (MAIA)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+763.3%

$12.00 average target

$1.39+0.01 (+0.7%)Latest market snapshot · Yahoo Finance

Market cap$84.5M

Cash$27.6M

Quarterly burn$5.3M

Pipeline assets2

Short float5.5%

Market expectations

Analyst Ratings & Price Targets

Data may be delayed

Street view at a glance

The average target implies 763.3% upsideTargets are estimates—not guarantees—and can change after company updates.

$12.00Average target

Wall Street consensus

Strong BuyBased on 2 analyst opinions

1ratings

Buy 1Hold 0Sell 0

Price-target range

$12.00

+763.3%

Low $10.00High $14.00

CurrentAverage

Bear case$10.00+619.4%

Base case$12.00+763.3%

Bull case$14.00+907.2%

Analyst coverage2published opinions

Bullish share100%buy recommendations

Target spread$4low-to-high dispersion

Consensus score1.01.0 is strongest

Recommendation mix

Current rating breakdown

1 tracked ratings

Company profile

About MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.